Home / Business and Economy / Johnson & Johnson Shares Soar: Undervalued or Overpriced?
Johnson & Johnson Shares Soar: Undervalued or Overpriced?
12 Nov
Summary
- Johnson & Johnson's stock has climbed 34.6% year-to-date
- Discounted Cash Flow analysis suggests the stock is undervalued by 54.8%
- Ongoing regulatory discussions in the pharmaceutical sector shape investor sentiment
As of November 12th, 2025, Johnson & Johnson's stock has been the subject of much debate among investors. The company's shares have shown solid momentum, climbing 3.7% in the last week and 1.6% over the past month, with a striking 34.6% year-to-date run.
Driving some of this share price action are recent developments, such as the company's acquisition in the medtech space and expanded strategic partnerships, both of which have fueled optimism about future growth. However, ongoing regulatory discussions in the pharmaceutical sector continue to shape investor sentiment.
According to a Discounted Cash Flow (DCF) analysis, Johnson & Johnson's intrinsic share value is estimated to be $428.83, implying the stock is currently trading at a 54.8% discount to its calculated intrinsic value. This suggests the company's shares may be undervalued, presenting a potential opportunity for investors.
